HaiZheng Pharmaceuticals: HS387 Tablets Obtained Approval Notice for New Drug Clinical Trials from the US FDA

HaiZheng Pharmaceuticals announced on December 22 that the company has received notice from the U.S. Food and Drug Administration that the clinical trial application for the HS387 tablets submitted by the company has been approved by the FDA, allowing clinical trials to be conducted in the United States. The HS387 tablets are intended for the treatment of advanced serous ovarian cancer, non-small cell lung cancer, and other late-stage solid tumors.